3
项与 Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Xi'an Jiaotong University) 相关的临床试验A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
This is a prospective, single-arm, single-center, open-label, single-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profile of LCAR-L10D in subjects with CD19- and/or CD22-positive relapsed/refractory B-cell lymphoma after prior adequate standard of care.
Safety and efficacy of dual CD19/CD22 targeted chimeric antigen receptor T cells for hematological malignancies
A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed and refractory acute B lymphoblastic leukemia.
100 项与 Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Xi'an Jiaotong University) 相关的临床结果
100 项与 Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Xi'an Jiaotong University) 相关的转化医学
100 项与 Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Xi'an Jiaotong University) 相关的专利(医药)
100 项与 Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Xi'an Jiaotong University) 相关的药物交易